GT Biopharma to host conference call to discuss second quarter 2021 results

BEVERLY HILLS, Calif., August 6, 2021 / PRNewswire / – GT Biopharma, Inc. (“GT Biopharma” or the “Company”) (NASDAQ: GTBP), a clinical-stage immuno-oncology company focused on the development of innovative therapies based on the natural killer cell The Company’s exclusive (NK) engage (TriKE â„¢) protein biology technology platform, today announced that the management team will host a conference call to discuss second quarter 2021 financial results and general updates on August 13, 2021 To 8:30 a.m. EST.

To join the call:

  • US callers should dial 1-877-870-4263 and international callers should dial 1-412-317-0790.
  • All participants must request to be connected to the GT Biopharma conference call.

The call will be available by visiting the “Presentations” page in the “News & Media” section of GT Biopharma’s website at A replay of the call will be archived for 30 days following the presentation.

About GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutics based on our proprietary NK TriKE â„¢ cell engagement platform. Our TriKE â„¢ platform is designed to harness and enhance the cancer killing capabilities of natural killer cells (NK cells) of a patient’s immune system. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota further develop and commercialize therapies using TriKE â„¢ technology. For more information, please visit

Forward-looking statements

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical direction and our current and proposed trials. Words and phrases reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes”, “hopes”, “intends”, “esteem”, “s ‘expects to’, ‘plans’, ‘plans’, ‘anticipates’ and their variations, or the use of the future, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Our forward-looking statements are not guarantees of performance, and actual results could differ materially from those contained or expressed by such statements. When evaluating all of these statements, we urge you to specifically consider the various risk factors identified in our Form 10-K for the year ended December 31, 2020, in the section titled “Risk Factors” in the section I, Section 1A, filed with the Securities and Exchange Commission (the “SEC”) on April 16, 2021, which could cause actual results to differ materially from those shown in our forward-looking statements.

Our forward-looking statements reflect our current views regarding future events and are based on current financial, economic, scientific and competitive data and information available on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of our cash position and our continued ability to raise additional capital to fund our operations, (ii) our ability to complete planned clinical trials, or meet FDA requirements for safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials by timely, (iv) our ability to achieve marketable product approval, (v) the design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of adverse clinical trial results, (vii) the market and commercialization of any product that is approved, (viii) the existence or development of treatments that are considered by healthcare professionals or patients nts as superior to our products, (ix) regulatory initiatives, compliance with government regulations and regulatory approval process and social conditions, and (x) various other matters, many of which are beyond our control. If one or more of these risks or uncertainties develop, or if the underlying assumptions prove to be incorrect, actual results may differ materially and adversely from those anticipated, believed, estimated or otherwise indicated by our forward-looking statements.

We intend that all forward-looking statements made in this press release be subject to the safe harbor protection of federal securities laws in accordance with Section 27A of the Securities Act, to the extent applicable. Except as required by law, we assume no responsibility to update these forward-looking statements to reflect events or circumstances that occur after the date of this press release. In addition, we assume no responsibility for informing you of the occurrence of unforeseen events that could cause actual results to differ from those expressed or implied by these forward-looking statements.


Institutional investors:
Brendan Payne
Stern Investor Relations, Inc.
[email protected]

Investor and media relations:
David Castaneda
[email protected]

Logo –

Previous Meet the Ivey MBA class of 2022
Next Treasury Department borrowing plans assume debt limit agreement - The North State Journal

No Comment

Leave a reply

Your email address will not be published.